Swimmer plot starting at first CAR T-cell therapy infusion. Remission status prior to CAR T-cell therapy infusions, subsequent lines of therapy, depth, timing, and duration of response to CAR T-cell therapy, MRD assessment, and death are depicted. A, leukapheresis; BOR, best overall response; C, cyclophosphamide; d, dexamethasone; D, daratumumab; E, elotuzumab; I, isatuximab; K, carfilzomib; MRD, minimal residual disease; P, pomalidomide; PD, progressive disease; pom-PACE, pomalidomide with cisplatin, doxorubicin, cyclophosphamide, and etoposide; PR, partial response; R, lenalidomide; S, selinexor; SD, stable disease; V, bortezomib; VGPR, very good partial response.